$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

$fold Overview Financials Valuation SEC Filings Company Website

2014 Q3 Form 10-Q Financial Statement

#000110465914077787 Filed on November 06, 2014

Income Statement

Concept	2014 Q3	2013 Q4	2013 Q3
Revenue	$293.0K	$320.0K	$39.00K
YoY Change	651.28%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.270M	$4.610M	$4.640M
YoY Change	13.58%	3.36%	-7.2%
% of Gross Profit
Research & Development	$12.05M	$9.120M	$10.11M
YoY Change	19.18%	-17.47%	-12.08%
% of Gross Profit
Depreciation & Amortization	$370.0K	$400.0K	$430.0K
YoY Change	-13.95%	-6.98%	2.38%
% of Gross Profit
Operating Expenses	$17.11M	$14.12M	$15.17M
YoY Change	12.75%	-11.31%	-10.3%
Operating Profit	-$16.82M		-$15.14M
YoY Change	11.11%		-10.53%
Interest Expense	$377.0K	$40.00K	$7.000K
YoY Change	5285.71%	-98.5%	-63.16%
% of Operating Profit
Other Income/Expense, Net	-$11.00K	$0.00	$0.00
YoY Change
Pretax Income	-$17.15M	-$15.75M	-$14.59M
YoY Change	17.55%	18.78%	-10.44%
Income Tax		-$3.510M	$0.00
% Of Pretax Income
Net Earnings	-$17.15M	-$12.24M	-$14.59M
YoY Change	17.55%	22.19%	-10.44%
Net Earnings / Revenue	-5852.9%	-3824.06%	-37407.69%
Basic Earnings Per Share
Diluted Earnings Per Share	-$217.4K	-$217.9K	-$294.0K
COMMON SHARES
Basic Shares Outstanding	78.70M shares	49.63M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q3	2013 Q4	2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$85.20M	$82.00M	$60.50M
YoY Change	40.83%	-17.26%	-43.03%
Cash & Equivalents	$19.70M	$43.64M	$30.05M
Short-Term Investments	$65.50M	$38.40M	$30.40M
Other Short-Term Assets	$1.762M	$5.195M	$1.700M
YoY Change	3.65%	128.85%	-44.75%
Inventory
Prepaid Expenses
Receivables	$300.0K	$1.100M	$2.100M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$87.24M	$88.28M	$64.30M
YoY Change	35.67%	-15.62%	-42.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.129M	$4.120M	$4.400M
YoY Change	-28.89%	-18.08%	-16.87%
Goodwill	$11.61M	$11.61M
YoY Change
Intangibles	$23.00M	$23.00M
YoY Change
Long-Term Investments		$0.00
YoY Change
Other Assets	$508.0K	$552.0K	$400.0K
YoY Change	27.0%	24.89%	-9.5%
Total Long-Term Assets	$38.25M	$39.29M	$4.800M
YoY Change	696.88%	618.06%	-16.3%
TOTAL ASSETS
Total Short-Term Assets	$87.24M	$88.28M	$64.30M
Total Long-Term Assets	$38.25M	$39.29M	$4.800M
Total Assets	$125.5M	$127.6M	$69.10M
YoY Change	81.6%	15.87%	-41.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.30M	$2.146M	$8.200M
YoY Change	37.8%	1.47%	-12.77%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.500M	$300.0K	$400.0K
YoY Change	525.0%	-25.0%	-20.0%
Total Short-Term Liabilities	$13.82M	$10.46M	$8.598M
YoY Change	60.78%	13.18%	-13.41%
LONG-TERM LIABILITIES
Long-Term Debt	$11.80M	$14.20M	$0.00
YoY Change		4633.33%	-100.0%
Other Long-Term Liabilities	$514.0K	$714.0K	$34.00M
YoY Change	-98.49%	-97.72%	9.32%
Total Long-Term Liabilities	$514.0K	$714.0K	$34.00M
YoY Change	-98.49%	-97.74%	7.94%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.82M	$10.46M	$8.598M
Total Long-Term Liabilities	$514.0K	$714.0K	$34.00M
Total Liabilities	$14.34M	$11.18M	$42.60M
YoY Change	-66.34%	-72.68%	2.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$426.2M	-$378.5M	-$366.3M
YoY Change	16.37%	18.7%	18.59%
Common Stock	$469.5M	$424.3M	$392.8M
YoY Change	19.54%	9.32%	1.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$43.28M	$45.75M	$26.49M
YoY Change
Total Liabilities & Shareholders Equity	$125.5M	$127.6M	$69.11M
YoY Change	81.59%	15.87%	-41.54%

Cashflow Statement

Concept	2014 Q3	2013 Q4	2013 Q3
OPERATING ACTIVITIES
Net Income	-$17.15M	-$12.24M	-$14.59M
YoY Change	17.55%	22.19%	-10.44%
Depreciation, Depletion And Amortization	$370.0K	$400.0K	$430.0K
YoY Change	-13.95%	-6.98%	2.38%
Cash From Operating Activities	-$15.12M	-$8.120M	-$13.51M
YoY Change	11.92%	10.18%	87.64%
INVESTING ACTIVITIES
Capital Expenditures	-$60.00K	-$50.00K	-$70.00K
YoY Change	-14.29%	-66.67%	-69.57%
Acquisitions
YoY Change
Other Investing Activities	-$29.42M	-$7.910M	$20.25M
YoY Change	-245.28%	-147.17%	-234.91%
Cash From Investing Activities	-$29.47M	-$7.970M	$20.18M
YoY Change	-246.04%	-147.98%	-232.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	22.36M	29.68M	-100.0K
YoY Change	-22460.0%	6352.17%	-100.56%
NET CHANGE
Cash From Operating Activities	-15.12M	-8.120M	-13.51M
Cash From Investing Activities	-29.47M	-7.970M	20.18M
Cash From Financing Activities	22.36M	29.68M	-100.0K
Net Change In Cash	-22.23M	13.59M	6.570M
YoY Change	-438.36%	40.1%	-243.45%
FREE CASH FLOW
Cash From Operating Activities	-$15.12M	-$8.120M	-$13.51M
Capital Expenditures	-$60.00K	-$50.00K	-$70.00K
Free Cash Flow	-$15.06M	-$8.070M	-$13.44M
YoY Change	12.05%	11.77%	92.83%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43640000	USD
CY2014Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	43640000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	19671000	USD
CY2014Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2000	USD
CY2013Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	81999000	USD
CY2014Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	85181000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	14000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1000	USD
CY2013Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5000	USD
CY2014Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-426228000	USD
CY2013Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	38360000	USD
CY2014Q3	fold	Cash Cash Equivalents And Short Term Investments Fair Value Disclosure CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure	85182000	USD
CY2013Q4	fold	Cash Cash Equivalents And Short Term Investments Fair Value Disclosure CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure	82000000	USD
CY2013Q4	fold	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000	USD
CY2013Q4	fold	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	6000	USD
CY2014Q3	fold	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	14000	USD
CY2014Q3	fold	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	13000	USD
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	38359000	USD
CY2013Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	38360000	USD
CY2014Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	65510000	USD
CY2014Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	65511000	USD
CY2013	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-13000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000	USD
CY2013	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
CY2014Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	42600000	USD
CY2013Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	23600000	USD
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2000	USD
CY2014Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	4000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-9000	USD
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14589000	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17149000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-47396000	USD
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	49621188	shares
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	78889346	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	49621188	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	70216251	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12884000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11516000	shares
CY2014Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	10200000	USD
CY2013Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	300000	USD
CY2013Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1200000	USD
	us-gaap	Restructuring Reserve Accrual Adjustment RestructuringReserveAccrualAdjustment	-74000	USD
CY2014Q3	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2014Q3	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-400000	USD
CY2013Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	10600000	USD
CY2013Q3	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	15838000	USD
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	49569000	USD
CY2013Q4	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	11600000	USD
CY2014Q3	us-gaap	Goodwill Goodwill	11613000	USD
CY2013Q4	us-gaap	Goodwill Goodwill	11613000	USD
CY2013Q4	us-gaap	Indefinitelived Intangible Assets Acquired IndefinitelivedIntangibleAssetsAcquired	23000000	USD
CY2014Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23000000	USD
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23000000	USD
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2014Q3	fold	Common Stock Voting Rights For Each Share Held CommonStockVotingRightsForEachShareHeld	1	item
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Restructuring Charges RestructuringCharges	2000000	USD
CY2013Q4	us-gaap	Restructuring Reserve RestructuringReserve	1842000	USD
CY2014Q3	us-gaap	Restructuring Reserve RestructuringReserve	407000	USD
	us-gaap	Payments For Restructuring PaymentsForRestructuring	-1361000	USD
CY2013Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1517000	USD
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1651000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4674000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4398000	USD
CY2013Q3	fold	Research Revenue ResearchRevenue	39000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	45751000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	127563000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Gross Noncurrent DeferredTaxLiabilitiesGrossNoncurrent	9186000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	714000	USD
CY2014Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	679000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	423593000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-378522000	USD
CY2013Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	1083000	USD
CY2013Q4	us-gaap	Other Assets Current OtherAssetsCurrent	5195000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	88278000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4120000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	552000	USD
CY2013Q4	us-gaap	Assets Assets	127563000	USD
CY2013Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	10162000	USD
CY2013Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	299000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10461000	USD
CY2013Q4	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	36677000	USD
CY2013Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	14174000	USD
CY2014Q3	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	65511000	USD
CY2014Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	293000	USD
CY2014Q3	us-gaap	Other Assets Current OtherAssetsCurrent	1762000	USD
CY2014Q3	us-gaap	Assets Current AssetsCurrent	87237000	USD
CY2014Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3129000	USD
CY2014Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	508000	USD
CY2014Q3	us-gaap	Assets Assets	125487000	USD
CY2014Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	11331000	USD
CY2014Q3	us-gaap	Liabilities Current LiabilitiesCurrent	13824000	USD
CY2014Q3	us-gaap	Secured Debt Current SecuredDebtCurrent	2493000	USD
CY2014Q3	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	36677000	USD
CY2014Q3	us-gaap	Secured Long Term Debt SecuredLongTermDebt	11809000	USD
CY2014Q3	us-gaap	Deferred Tax Liabilities Gross Noncurrent DeferredTaxLiabilitiesGrossNoncurrent	9186000	USD
CY2014Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	514000	USD
CY2014Q3	us-gaap	Common Stock Value CommonStockValue	853000	USD
CY2014Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	468650000	USD
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	43277000	USD
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	125487000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9973000	USD
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	61975416	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61975416	shares
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	79257588	shares
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	79257588	shares
CY2014Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11157000	USD
CY2013Q3	us-gaap	Sales Revenue Net SalesRevenueNet	39000	USD
CY2014Q3	fold	Research Revenue ResearchRevenue	293000	USD
CY2014Q3	us-gaap	Sales Revenue Net SalesRevenueNet	293000	USD
	fold	Research Revenue ResearchRevenue	39000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	39000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	1224000	USD
	fold	Research Revenue ResearchRevenue	1224000	USD
CY2013Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	10110000	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4635000	USD
CY2013Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	429000	USD
CY2014Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	12049000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	32824000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	32019000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15199000	USD
	us-gaap	Restructuring Charges RestructuringCharges	-74000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1183000	USD
	us-gaap	Operating Expenses OperatingExpenses	47927000	USD
	us-gaap	Operating Expenses OperatingExpenses	48430000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1318000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14288000	USD
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5270000	USD
CY2014Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-600000	USD
CY2014Q3	us-gaap	Restructuring Charges RestructuringCharges	15000	USD
CY2014Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	375000	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	17109000	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	15174000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-15135000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-16816000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-48391000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-46703000	USD
CY2013Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	36000	USD
CY2014Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	55000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	147000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	133000	USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	7000	USD
CY2014Q3	us-gaap	Interest Expense InterestExpense	377000	USD
	us-gaap	Interest Expense InterestExpense	26000	USD
	us-gaap	Interest Expense InterestExpense	1106000	USD
CY2013Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-517000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-874000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-30000	USD
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-11000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-14589000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-17149000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-47396000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-47706000	USD
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.22
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.96
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.68
CY2013Q3	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	2000	USD
CY2014Q3	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	4000	USD
	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-9000	USD
	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	1000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2000	USD
CY2014Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	4000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-9000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1000	USD
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14587000	USD
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17145000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-47405000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-47705000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	176000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4398000	USD
	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-790000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3433000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-26000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1213000	USD
	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities	-200000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-37161000	USD
	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-1064000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-618000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-679000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	3601000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-37674000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4674000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	68348000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	33654000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	645000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	34049000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-27342000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	47959000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	75109000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	192000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	38736000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	299000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	299000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2097000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	40534000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-299000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-3924000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-23969000	USD
	us-gaap	Interest Paid InterestPaid	24000	USD
	us-gaap	Interest Paid InterestPaid	864000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33971000	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30047000	USD
	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P1Y
CY2014Q3	fold	Number Of Patients With Glphek Amenable Mutation Who Completed Study012 NumberOfPatientsWithGLPHEKAmenableMutationWhoCompletedStudy012	48	item
CY2014Q3	fold	Number Of Patients Elected To Continue With Treatment Extension NumberOfPatientsElectedToContinueWithTreatmentExtension	46	item
CY2014Q3	fold	Patients Elected To Continue With Twelve Month Treatment Extension Percent PatientsElectedToContinueWithTwelveMonthTreatmentExtensionPercent	0.96	pure
CY2014Q3	fold	Term Of Treatment Extension TermOfTreatmentExtension	P12M
CY2014Q3	fold	Number Of Patients Remain On Migalastate NumberOfPatientsRemainOnMigalastate	45	item

Files In Submission

Name	View Source	Status
0001104659-14-077787-index-headers.html	Edgar Link	pending
0001104659-14-077787-index.html	Edgar Link	pending
0001104659-14-077787.txt	Edgar Link	pending
0001104659-14-077787-xbrl.zip	Edgar Link	pending
a14-19832_110q.htm	Edgar Link	pending
a14-19832_1ex31d1.htm	Edgar Link	pending
a14-19832_1ex31d2.htm	Edgar Link	pending
a14-19832_1ex32d1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fold-20140930.xml	Edgar Link	completed
fold-20140930.xsd	Edgar Link	pending
fold-20140930_cal.xml	Edgar Link	unprocessable
fold-20140930_def.xml	Edgar Link	unprocessable
fold-20140930_lab.xml	Edgar Link	unprocessable
fold-20140930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

2014 Q3 Form 10-Q Financial Statement

#000110465914077787 Filed on November 06, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD AMICUS THERAPEUTICS, INC. Stock $fold

2014 Q3 Form 10-Q Financial Statement

#000110465914077787 Filed on November 06, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold